(NASDAQ:THTX) MONTREAL, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that two leading independent proxy advisory firms, Institutional Shareholders Services Inc. (“ISS”) and Glass Lewis & Co. LLC (“Glass Lewis”), have each recommended that the shareholders of the Company (the “Shareholders”) vote “FOR” the special resolution (the “Arrangement Resolution”) to approve the plan of arrangement (the “Arrangement”) involving the Company and CB Biotechnology, LLC (the “Purchaser”), an affiliate of Future Pak, LLC (“Future Pak”), a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products.
Related Questions
What are the specific terms and valuation of the arrangement with Future Pak, and how will it impact Theratechnologies' balance sheet and cash flow?
How likely is it that the proxy advisor recommendations will translate into sufficient shareholder support to pass the Arrangement Resolution?
What strategic synergies and operational advantages does the partnership with Future Pak provide, and how might it affect Theratechnologies' drug development timeline and commercial outlook?